tiprankstipranks
Accendra Health (ACH)
NYSE:ACH
US Market
Want to see ACH full AI Analyst Report?

Accendra Health (ACH) Earnings Dates, Call Summary & Reports

558 Followers

Earnings Data

Report Date
Jul 31, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.08
Last Year’s EPS
0.26
Same Quarter Last Year
Based on 4 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 11, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a mix of strong strategic and financial progress — notably the successful separation, margin transformation, balance sheet optimization commitments, $82M equipment sale and $52M one‑time gain, and operational wins in sleep therapy — while also acknowledging meaningful near‑term pressures: a 6.8% revenue decline, collection and cost headwinds, slightly negative free cash flow in Q1, and an expected ~ $40M annualized increase in cash interest post‑refinancing. Management emphasized that underlying revenue (ex‑large payor) was roughly +1% and that debt reduction and cost‑savings remain priorities, framing the near‑term drawbacks as manageable steps in service of a stronger long‑term standalone profile.
Company Guidance
The company affirmed its 2026 outlook for revenue and adjusted EBITDA and said it expects revenue to ramp through the year with at least 65% of adjusted EBITDA earned in Q3–Q4; Q1 results included a 6.8% revenue decline (which would be ~+1% ex the exited large commercial payor) and $58 million of adjusted EBITDA, with free cash flow slightly negative. Management closed an $82 million cash sale of patient equipment (producing a $52 million book gain excluded from adjusted EBITDA), reported $337 million of cash, $195 million of available revolver capacity, and net debt essentially flat at $1.77 billion after $19 million of IRS and $22 million of P&HS divestiture payments in the quarter. The announced balance‑sheet optimization will pay off 2027 maturities, offer exchanges that could de‑leverage by up to ~$115 million, issue new first‑ and second‑lien notes maturing in 2032/2033, provide a new $300 million committed revolver due 2030, and double the weighted‑average life of the debt to ~5.5 years. The financing is expected to launch in the coming week with closing targeted for mid–late June; the company cautioned annualized cash interest will be ~ $40 million higher (with about half of that hitting in H2 2026) even as it pursues continued cost savings, better collections and rapid de‑leveraging.
Successful Separation and Stand‑Alone Positioning
Transition services and separation from Owens & Minor are on track; Accendra is now operating as a pure‑play home‑based care company focused on growth and higher margins.
Completed Large Payor Transition with Cash Proceeds
Sold patient service equipment related to the exited large commercial payor for $82 million in cash proceeds, generating a book gain of $52 million (one‑time, excluded from adjusted EBITDA).
Balance Sheet Optimization and Debt Extension
Announced comprehensive balance sheet optimization with lender commitments to: pay off 2027 maturities, extend 2029/2030 notes via exchange offers (new secured notes maturing 2032/2033), and a new $300M revolver due 2030. Expected de‑leveraging of up to ~$115 million and doubling of weighted average debt life to ~5.5 years.
Strong Margin Transformation
Company highlighted a structural transformation from ~19% gross margins and ~4% EBITDA margins pre‑divestiture to nearly 50% gross margins and double‑digit EBITDA margins as a stand‑alone home‑based care business.
Q1 Adjusted EBITDA in Line with Expectations
Reported first quarter adjusted EBITDA of $58 million, consistent with management expectations despite headwinds.
Comfortable Liquidity and Covenant Compliance
Ended the quarter with $337 million cash on the balance sheet, $195 million available on the committed revolver, and in compliance with debt covenants.
Underlying Revenue Growth Excluding Large Payor Impact
Reported total revenue decline of 6.8% for the quarter; excluding the impact of the exited large commercial payor, underlying revenue growth would have been approximately +1%.
Operational Wins in Sleep and Other Categories
Sleep Journey program drove higher revenue per order, lower attrition and improved therapy adherence (adherence improving by single‑digit percentage points quarter‑over‑quarter). Sleep Center of Excellence piloted successfully in 3 markets (nationwide rollout continuing), and category growth included a sleeve category up >4% and home respiratory ~4%; urology and ostomy also led growth.

Accendra Health (ACH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ACH Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 31, 2026
2026 (Q2)
-0.08 / -
0.26
May 11, 2026
2026 (Q1)
-0.10 / -0.04
0.23-117.39% (-0.27)
Feb 19, 2026
2025 (Q4)
0.22 / 0.21
0.55-61.82% (-0.34)
Oct 30, 2025
2025 (Q3)
0.23 / 0.25
0.42-40.48% (-0.17)
Aug 11, 2025
2025 (Q2)
0.28 / 0.26
0.36-27.78% (-0.10)
May 08, 2025
2025 (Q1)
0.20 / 0.23
0.1921.05% (+0.04)
Feb 28, 2025
2024 (Q4)
0.52 / 0.55
0.69-20.29% (-0.14)
Nov 04, 2024
2024 (Q3)
0.41 / 0.42
0.44-4.55% (-0.02)
Aug 02, 2024
2024 (Q2)
0.33 / 0.36
0.18100.00% (+0.18)
May 03, 2024
2024 (Q1)
0.18 / 0.19
0.05280.00% (+0.14)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ACH Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 11, 2026
$3.58$3.89+8.66%
Feb 19, 2026
$2.48$2.61+5.24%
Oct 30, 2025
$4.96$3.97-19.96%
Aug 11, 2025
$7.09$4.63-34.70%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Accendra Health (ACH) report earnings?
Accendra Health (ACH) is schdueled to report earning on Jul 31, 2026, Before Open (Confirmed).
    What is Accendra Health (ACH) earnings time?
    Accendra Health (ACH) earnings time is at Jul 31, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ACH EPS forecast?
          ACH EPS forecast for the fiscal quarter 2026 (Q2) is -0.08.